JanOne Inc. Overview
Pro stress-test →JanOne Inc. (NASDAQ:JAN), a biotechnology company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties. The company is starting with Peripheral Artery Disease (PAD), a condition that affects over 8.5 million Americans, many of whom are at risk for addiction when opioids are prescribed to treat the associated pain.
Strategic Profile
Pro stress-test →JanOne's mission is to bring treatments to the market for diseases that cause severe pain and to find non-addictive answers for treating pain. Its lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain.
Competitive Landscape
Pro stress-test →JanOne competes in the clinical-stage biotech space developing non-opioid pain therapies. Primary competition comes from other specialized pain management and addiction treatment companies, as well as larger pharmaceutical companies exploring non-addictive pain solutions. The company's focus on the opioid crisis aligns it with broader therapeutic trends but faces competition from both traditional pharma and emerging biotech players.
Industry Context
JanOne Inc. operates in Clinical-stage biopharmaceutical development - pain and addiction therapeutics.
Key facts
Founded: 1976 · Headquarters: Las Vegas, US · Employees: N/A · Revenue: N/A · Market cap: $27.14M